<DOC>
	<DOC>NCT02184741</DOC>
	<brief_summary>To estimate the safety and efficacy of intravenous immunoglobulin therapy using GB-0998 in women with four or more miscarriages by carrying out randomized, placebo-controlled, double-blinded studyï¼Ž</brief_summary>
	<brief_title>Evaluation of the Safety and Efficacy of GB-0998 in Unexplained Primary Recurrent Miscarriage</brief_title>
	<detailed_description />
	<mesh_term>Abortion, Spontaneous</mesh_term>
	<mesh_term>Abortion, Habitual</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1. Patients who have no experience of a live birth. 2. Patients with four or more miscarriages. 3. Patients who have not any obvious cause of recurrent miscarriage, or who have a miscarriage even after appropriate treatments. 1. Patients who have abnormality with karyotype analysis in either the patients or their partners. 2. Patients who were diagnosed antiphospholipid antibody syndrome according international criteria. 3. Patients with no receiving of appropriate treatment in spite of diagnosis of diabetes or impaired glucose tolerance. 4. Patients who have experience of receiving IVIg as the treatment of recurrent miscarriages. 5. Patients with receiving treatment of malignancy. 6. Patients with history of thromboembolism. 7. Patients with history of shock or hypersensitivity to GB0998. 8. Patients with hereditary fructose intolerance or IgA deficiency.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>IVIG</keyword>
	<keyword>Unexplained Recurrent miscarriage</keyword>
	<keyword>Recurrent abortion</keyword>
	<keyword>Intravenous immunoglobulin</keyword>
</DOC>